Faculty Collaboration Database

Initial clinical experience with IV tissue plasminogen activator for acute ischemic stroke: a multicenter survey. The t-PA Stroke Survey Group. Neurology 1999 Jul 22;53(2):424-7

Date

08/03/1999

Pubmed ID

10430444

DOI

10.1212/wnl.53.2.424

Scopus ID

2-s2.0-0033595255 (requires institutional sign-in at Scopus site)   166 Citations

Abstract

We assessed initial clinical experience with IV tissue plasminogen activator (t-PA) treatment of acute ischemic stroke in a standardized retrospective survey of hospitals with experienced acute stroke treatment systems. The incidence of symptomatic intracerebral hemorrhage (ICH) was 6% (11 of 189 patients; 95% CI 3 to 11%), similar to that in the National Institute of Neurological Disorders and Stroke (NINDS) t-PA Stroke Study. Deviations from the NINDS protocol guidelines were identified in 30% of patients (56 of 189). The incidence of symptomatic ICH was 11% among patients with protocol deviations as compared with 4% in patients who were treated according to the NINDS protocol guidelines, suggesting that strict adherence to protocol guidelines is prudent.

Author List

Tanne D, Bates VE, Verro P, Kasner SE, Binder JR, Patel SC, Mansbach HH, Daley S, Schultz LR, Karanjia PN, Scott P, Dayno JM, Vereczkey-Porter K, Benesch C, Book D, Coplin WM, Dulli D, Levine SR

Authors

Jeffrey R. Binder MD Professor in the Neurology department at Medical College of Wisconsin
Diane S. Book MD Professor in the Neurology department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Aged
Brain Ischemia
Cerebrovascular Disorders
Female
Humans
Infusions, Intravenous
Male
Middle Aged
Retrospective Studies
Tissue Plasminogen Activator